ArticleRadiation oncology (London, England)2026
Gamma Knife treatment of papillary craniopharyngioma: a single-center study of tumor control and predictors of progression.
Article in Radiation oncology (London, England), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundPapillary craniopharyngioma (PCP) is a rare sellar tumor distinct from adamantinomatous type. Although Gamma Knife radiosurgery (GKRS) treats craniopharyngiomas effectively, dedicated PCP-only GKRS outcome series are scarce. We evaluated tumor control and prognostic factors following GKRS for PCP.
methodsWe retrospectively analyzed 34 patients with histologically confirmed PCP who underwent GKRS at Beijing Tiantan Hospital (2002-2025) for residual/recurrent disease after surgery. Primary endpoint was progression-free survival (PFS). Kaplan-Meier and Cox regression analyses identified prognostic factors.
resultsThirty-four patients (18 males, mean age 41.7 ± 13.6 years) received GKRS with median marginal dose 12 Gy to median tumor volume 1.10 cm³. With a median clinical follow-up of 54.10 months, the 1-, 3-, and 5-year PFS rates were 91.18%, 82.35%, and 73.53%, respectively. Overall survival was 94.12%. Disease control rate was 70.59%. Exploratory analysis with limited statistical power (10 events, EPV = 3.3) suggested potential associations between tumor volume > 1.1 cm³ (HR = 3.86, P = 0.061) and preoperative hypogonadism (HR = 3.94, P = 0.058) with progression, though these findings require validation in larger cohorts. Visual deterioration was significantly higher in progression group (80.0% vs. 16.7%, P = 0.002). Most patients (61.8%) maintained good quality of life.
conclusionGKRS provides effective long-term tumor control for postoperative PCP patients with acceptable safety profile. Exploratory hypothesis-generating analysis suggested potential associations between tumor volume and preoperative gonadal function status with progression, though these findings require validation in adequately powered studies. These findings support GKRS as a valuable treatment option in the multimodal management of PCP, particularly for patients with residual or recurrent disease after surgery.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.